Precedia vs. general AI
General chatbots are good at language. Nonclinical decisions need something else: the regulator's exact words, a complete set of precedents, and honesty about what isn't public.
| General AI chatbot | Precedia | |
|---|---|---|
| Where answers come from | Training data, sometimes a web search | FDA and EMA review documents and US labels for approved products |
| Citations | Often missing; when given, not always real | Every answer cites the document and page. Every quote is verified word for word |
| When the source is silent | Tends to fill the gap with a plausible answer | Shows “Not stated in public reviews” |
| Counting precedents | Can't reliably tell you “how many of all approvals” | Covers every approval in five modalities, so counts are real |
| Recency | Stops at the model's training cutoff | Sources checked every week; data updated every month, with the date on every page |
| What you take away | Chat text | Cited answers, precedent tables, a plan benchmark, CSV and a cited report |
Why it matters for an IND package
Precedia reads the FDA multi-discipline reviews, EMA assessment reports and CBER review memos themselves. A general chatbot paraphrases whatever it absorbed in training.
Every quote is checked word for word against the page it cites. A build that fails the check never ships.
“3 of 18 multispecifics disclosed their first-dose method” only means something if you have all 18. Precedia covers every approval in each of its modalities.
When a review is silent, Precedia shows the gap. It never fills it with a plausible-sounding guess.
Precedia checks FDA, EMA and ICH every week for new approvals, review documents and guidance, and publishes an update on the first Monday of each month. A chatbot's knowledge stops at its training cutoff.
Benchmark your plan against precedents and take the citations straight into briefing documents, with the page number attached.
Try it yourself
Ask your usual chatbot these questions, then open the Precedia answer and check the page it cites.
- How was the first-in-human dose set for approved multispecifics?
- Which tox species did Columvi use, and why?
- Which nonclinical studies did approved gene therapies skip?
Ask Lidia is in private beta.